Glaukos Corporation logo

GKOS

Healthcare

Glaukos Corporation

$135.27+1.85 (+1.39%)PRE

Live · NYSE · May 9, Close

AI Insight

What's Moving GKOS Today?

No stock-specific AI insight has been generated for GKOS yet. Check back soon — insights are generated from recent news analysis.

Fundamentals

Market Cap$7.9B
P/E Ratio
EPS
Dividend Yield
Dividend / Share
ROE
Profit Margin
Debt / Equity

Trading

Volume889K
Avg Volume (10D)
Shares Outstanding58.5M

GKOS News

20 articles

All 20 articles loaded

Price Data

Open$133.69
Previous Close$133.42
Day High$136.41
Day Low$131.35
52 Week High
52 Week Low

About Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

1.1K employees
Listed June 25, 2015
HealthcareSURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Company Details

Security TypeStock
ExchangeNYSE
Currency
Round Lot
SICSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
CIK
Composite FIGI
Share Class FIGI